0001558370-21-011671 | 6-K | XBRL Viewer

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2021
Document Information [Line Items]
Entity Registrant Name	Evaxion Biotech A/S
Entity Central Index Key	0001828253
Document Type	6-K
Document Period End Date	Jun. 30, 2021
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Amendment Flag	false

Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Operating expenses:
Research and development	$ 5,111	$ 2,570	$ 9,004	$ 5,080
General and administrative	1,915	1,372	3,197	2,153
Total operating expenses	7,026	3,942	12,201	7,233
Operating loss	(7,026)	(3,942)	(12,201)	(7,233)
Finance income	33	6	1,005	22
Finance expenses	(495)		(792)	(4)
Net loss before tax	(7,488)	(3,936)	(11,988)	(7,215)
Income tax benefit	669	296	1,076	476
Net loss for the period	(6,819)	(3,640)	(10,912)	(6,739)
Net loss attributable to shareholders of Evaxion Biotech A/S	(6,819)	(3,640)	(10,912)	(6,739)
Other comprehensive income that may be reclassified to profit or loss in subsequent periods:
Exchange differences on translation of foreign operations	(57)	(10)	(28)	(10)
Tax on other comprehensive income	6
Other comprehensive income that will not be reclassified to profit or loss in subsequent periods:
Exchange differences on currency translation to presentation currency	474	109	(284)	(71)
Other comprehensive loss for the period, net of tax	423	99	(312)	(81)
Total comprehensive loss	(6,396)	(3,541)	(11,224)	(6,820)
Total comprehensive loss attributable to shareholders of Evaxion Biotech A/S	$ (6,396)	$ (3,541)	$ (11,224)	$ (6,820)
Loss per share - basic and diluted	$ (0.36)	$ (0.24)	$ (0.59)	$ (0.44)

Unaudited Condensed Consolidated Interim Statements of Financial Position - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Non-current assets
Intangible assets	$ 97	$ 100
Deferred tax assets	252	262
Property and equipment	2,076	221
Government grants receivable	549	194
Tax receivables	1,058
Leasehold deposits	200	238
Total non-current assets	4,232	1,015
Current assets
Prepayments and other receivables	2,564	1,553
Deferred offering costs	265	1,729
Government grants receivable	421	418
Tax receivables	1,376	1,416
Cash and cash equivalents	18,799	5,834
Total current assets	23,425	10,950
TOTAL ASSETS	27,657	11,965
EQUITY AND LIABILITIES
Share capital	3,132	2,648
Other reserves	56,168	31,669
Accumulated deficit	(37,471)	(27,279)
Total equity	21,829	7,038
Non-current liabilities
Lease liabilities	974
Provisions	53
Total non-current liabilities	1,027
Current liabilities
Lease liabilities	136	20
Trade payables	1,552	2,646
Other payables	3,113	2,261
Total current liabilities	4,801	4,927
Total liabilities	5,828	4,927
TOTAL EQUITY AND LIABILITIES	$ 27,657	$ 11,965

Unaudited Condensed Consolidated Interim Statements of Changes in Equity kr in Thousands, $ in Thousands	Share capital USD ($)	Share capital DKK (kr)	Share premium USD ($)	Foreign currency translation reserve USD ($)	Accumulated deficit USD ($)	USD ($)
Equity at Dec. 31, 2019	$ 2,481		$ 22,862	$ (169)	$ (15,812)	$ 9,362
Net loss for the period					(3,099)	(3,099)
Other comprehensive income				(180)		(180)
Share-based compensation					680	680
Equity at Mar. 31, 2020	2,481		22,862	(349)	(18,231)	6,763
Equity at Dec. 31, 2019	2,481		22,862	(169)	(15,812)	9,362
Net loss for the period						(6,739)
Equity at Jun. 30, 2020	2,481		22,862	(250)	(21,376)	3,717
Equity at Mar. 31, 2020	2,481		22,862	(349)	(18,231)	6,763
Net loss for the period					(3,640)	(3,640)
Other comprehensive income				99		99
Share-based compensation					495	495
Equity at Jun. 30, 2020	2,481		22,862	(250)	(21,376)	3,717
Equity at Dec. 31, 2020	2,648	kr 16,198	31,443	226	(27,279)	7,038
Net loss for the period					(4,093)	(4,093)
Other comprehensive income				(729)		(729)
Tax effects on other comprehensive income				(6)		(6)
Share-based compensation					294	294
Issuance of shares for cash	484		29,516			30,000
Transaction costs			(4,705)			(4,705)
Equity at Mar. 31, 2021	3,132		56,254	(509)	(31,078)	27,799
Equity at Dec. 31, 2020	2,648	16,198	31,443	226	(27,279)	7,038
Net loss for the period						(10,912)
Equity at Jun. 30, 2021	3,132	19,198	56,254	(86)	(37,471)	21,829
Equity at Mar. 31, 2021	3,132		56,254	(509)	(31,078)	27,799
Net loss for the period					(6,819)	(6,819)
Other comprehensive income				417		417
Tax effects on other comprehensive income				6		6
Share-based compensation					426	426
Equity at Jun. 30, 2021	$ 3,132	kr 19,198	$ 56,254	$ (86)	$ (37,471)	$ 21,829

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2020-01-01
-Paragraph 18
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2020-01-01

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2020-01-01
-Paragraph 24
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2020-01-01

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2020-01-01
-Paragraph 32
-Subparagraph a
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2020-01-01

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 28
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2020-01-01

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2020-01-01
-Paragraph 39L
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2020-en-b&anchor=para_39L_e&doctype=Standard
-URIDate 2020-01-01

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 23
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_23&doctype=Standard
-URIDate 2020-01-01

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2020-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2020-01-01

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 106
-Subparagraph d
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d_i&doctype=Standard
-URIDate 2020-01-01

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Note Effective 2021-01-01
-Name IFRS
-Number 17
-IssueDate 2020-01-01
-Paragraph 113
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_113_b&doctype=Standard
-URIDate 2020-01-01

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 81A
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_81A_a&doctype=Standard
-URIDate 2020-01-01

+ Details

Unaudited Condensed Consolidated Interim Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Operating activities:
Net loss for the period	$ (10,912)	$ (6,739)
Adjustments for non-cash items	(908)	735
Income taxes received		812
Interest paid	(3)
Cash flow from operating activities before changes in working capital	(11,823)	(5,192)
Cash flow from changes in working capital:
Changes in net working capital	300	(61)
Net cash used in operating activities	(11,523)	(5,253)
Investing activities:
Investment in intangible assets	(60)	(35)
Purchase of property and equipment	(792)	(74)
Receipt (payment) of non-current financial assets - leasehold deposits	30	(17)
Net cash used in investing activities	(822)	(126)
Financing activities:
Proceeds from issuance of shares	27,900
Transaction costs related to issuance of shares	(2,605)
Leasing installments	(78)	(36)
Net cash provided by/ (used in) financing activities	25,217	(36)
Net increase/ (decrease) in cash and cash equivalents	12,872	(5,415)
Cash and cash equivalents at January 1	5,834	9,559
Exchange rate adjustments on cash and cash equivalents	93	(59)
Cash and cash equivalents at June 30	$ 18,799	$ 4,085

General Company Information

6 Months Ended

Jun. 30, 2021

General Company Information

General Company Information

Note 1. General Company Information

Evaxion Biotech A/S (the “Company” or “Evaxion”) is an artificial intelligence (“AI”)-immunology platform company that uses its proprietary AI technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop immunotherapies for patients in the global market. Unless the context otherwise requires, references to the “Company,” “we,” “us,” and “our”, refer to Evaxion Biotech A/S and its subsidiaries.

Evaxion is a public limited liability company incorporated and domiciled in Denmark with its registered office located at Dr. Neergaards Vej 5f, DK-2970 Hørsholm, Denmark.

On February 5, 2021, the Company completed an initial public offering which resulted in the listing of American Depositary Shares, or ADSs, representing the Company's ordinary shares, under the symbol "EVAX" in the United States on The Nasdaq Capital Market.

The unaudited condensed consolidated interim financial statements of Evaxion Biotech and its subsidiary (collectively, the “Group”) for the three and six months ended June 30, 2021 and 2020, were approved, and authorized for issuance, by the Audit Committee of the board of directors on August 10, 2021.

Liquidity

We anticipate incurring additional losses until such time, if ever, we can complete our research and development (“R&D”) activities and obtain an out-licensing partnership for our product candidates and generate revenues from such product candidates. Substantial additional financing will be needed by us to fund our operations and to continue development of our product candidates.

We expect to finance cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements.

We may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of current shareholders could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of the current shareholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, licenses and other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable and/or may reduce the value of our ordinary shares. Failure to raise capital or enter into such other arrangements when needed could have a negative impact on financial conditions and our ability to pursue our business plans and strategies. If we are unable to raise additional capital when needed, we could be forced to delay, limit, reduce or terminate our product candidate development or grant rights to develop and market our product candidates.

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2021

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

Basis of preparation

The unaudited condensed consolidated interim financial statements of the Company are prepared in accordance with International Accounting Standard 34, Interim Financial Reporting. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with International Financial Reporting Standards (“IFRS”) have been condensed or omitted. Accordingly, these unaudited condensed consolidated interim financial statements should be read in conjunction with the Company’s audited annual consolidated financial statements for the year ended December 31, 2020 and accompanying notes, which have been prepared in accordance with IFRS as issued by the International Accounting Standards Board.

The accounting policies applied are consistent with the accounting policies as outlined in the basis of presentation section included in Note 2 of the audited financial statements as of and for the year ended December 31, 2020. As of January 1, 2021, the following accounting policy in respect of foreign currency translation is now relevant:

Intragroup receivables to foreign operations for which settlement is neither planned nor likely to occur in the foreseeable future are treated as part of the net investment, and the gain or loss on foreign currency translation of such receivables is recognized in other comprehensive income and classified as part of the foreign currency translation reserve.

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates and requires management to exercise its judgment in the process of applying the Company’s accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the unaudited condensed consolidated interim financial statements are disclosed in Note 3.

Right-of-use assets

The Company recognizes a right-of-use asset at the lease commencement date (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost less any accumulated depreciation and impairment losses and adjusted for certain remeasurements of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, lease payments made at or before the commencement date less any lease incentives received, initial direct costs incurred, and restoration costs.

Right-of-use assets are depreciated over the shorter of the lease term and the useful life of the right-of-use asset using the straight-line method. In addition, right-of-use assets are reduced by impairment losses, if any, and adjusted for certain remeasurements.

The Company’s right-of-use assets are presented within property and equipment.

Property and equipment

Property and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Depreciation is recognized on a straight-line basis over the estimated useful lives of the assets, as follows:

Assets		Useful life
Properties		Shorter of lease term and useful life of the asset
Other equipment		3 – 6 years

Reclassifications of prior period presentation

Certain items in prior year condensed consolidated financial statements have been reclassified to conform to the current period’s presentation.

Standards issued but not yet effective

There were a number of standards and interpretations which were issued but were not yet effective at June 30, 2021 and have not been adopted for these financial statements, including:

●

Amendments to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or Non-current (January 1, 2023)

●

Amendment to IAS 37 Provisions, contingent liabilities and contingent assets, Onerous Contracts— Cost of Fulfilling a Contract (January 1, 2022)

●

Amendments to IAS 16 Property, Plant and Equipment, proceeds before intended use (January 1, 2022)

●

Annual Improvements 2018-2020 (January 1, 2022)

●

Amendment to IAS 1 Presentation of Financial Statements: Disclosure of Accounting Policies (January 1, 2023)

●

Amendment to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors: Definition of Accounting Estimates (January 1, 2023)

●

Amendments to IFRS 16 Leases: COVID-19-Related Rent Concessions beyond June 30, 2021 (April 1, 2021)

The Company expects to adopt these standards, updates and interpretations when they become mandatory. These standards are not expected to have a significant impact on disclosures or amounts reported in the Company’s financial statements in the period of initial application and future reporting periods.

Significant Accounting Judgements, Estimates, and Assumptions

6 Months Ended

Jun. 30, 2021

Significant Accounting Judgements, Estimates, and Assumptions

Significant Accounting Judgements, Estimates, and Assumptions

Note 3. Significant Accounting Judgements, Estimates, and Assumptions

In the application of our accounting policies, the Company is required to make judgments, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The unaudited condensed consolidated interim financial statements do not include all disclosures for critical accounting judgments and estimation uncertainties that are required in the annual consolidated financial statements, and therefore, should be read in conjunction with the Company’s audited consolidated financial statements as of and for the year ended December 31, 2020.

Significant accounting estimates made in the process of applying our accounting policies and that have the most significant effect on the amounts recognized in our unaudited condensed consolidated interim financial statements relate to share-based compensation. See Note 5 below for additional information regarding stock-based compensation.

There have been no other changes to the application of critical accounting judgments, or estimation uncertainties regarding accounting estimates.

Significant Events in the Reporting Period

6 Months Ended

Jun. 30, 2021

Significant Events in the Reporting Period

Significant Events in the Reporting Period

Note 4. Significant Events in the Reporting Period

Impact from COVID-19

The Company is closely monitoring the potential impact of COVID-19 on the 2021 financial results and cash flows and beyond. The Company’s top priority remains the health and safety of its staff and the patients in the studies. The Company maintains compliance with government and health authorities. Additionally, we have adapted the way in which we work to ensure we are doing our part in reducing transmission of COVID-19.

The Company has worked closely with laboratories and investigators to ensure safe continuation and working requirements of our ongoing research activities and human clinical trials. The Company has not experienced a materially negative impact from COVID-19. As of June 30, 2021, the impact of the COVID-19 pandemic continues to unfold. As events continue to evolve and additional information becomes available, our estimates may change materially in the future.

While business travel has been suspended, the Company has remained active and effective in the process of raising capital with institutional investors by conducting key meetings on a virtual basis.

Share-Based Payments

6 Months Ended

Jun. 30, 2021

Share-Based Payments

Share-Based Payments

Note 5. Share-Based Payments

Warrant Program and Amendments

The Company’s Articles of Association allow for the granting of equity compensation, in the form of equity settled warrants, to employees, consultants and Scientific Advisory Board members who provide services similar to employees, members of executive management, and the board of directors. The warrants granted in 2018 or prior become exercisable upon an exit event, which triggers an immediate vesting, or at any time as determined by the board of directors in accordance with the terms of the plan. The warrants granted in 2020 vest either gradually over 36 months or vest immediately. Vested warrants granted in 2020 are exercisable in certain exercise windows beginning in the second half of the year of 2021. Warrants granted up until 2019 expire on December 31, 2036. Warrants granted in 2020 expire on December 31, 2031. For the six months ended June 30, 2021 and 2020, the number of warrants as a percentage of outstanding ordinary shares was 11.8% and 12.3%, respectively.

On January 4, 2021, the Company effected its Stock Split which also resulted in a reduction of the nominal value of the Company’s ordinary shares from DKK 2 to DKK 1. In accordance with the anti-dilution provisions of the warrant agreements, the number of warrants was increased by a ratio of 36 to 1 and the exercise price was decreased from DKK 2 to 1 DKK. Accordingly, information related to the Company’s warrants, have been retroactively adjusted to reflect the stock split and the bonus shares for all periods presented.

The following schedule specifies the granted warrants:


		Weighted Average
		Exercise
	Number of	Price/Share
	warrants	(DKK)
Warrants granted as at December 31, 2020	2,228,076	1
Warrants granted	63,809	1
Warrants forfeited	(7,566)	1
Warrants cancelled	(10,404)	1
Warrants granted as at June 30, 2021	2,273,915	1
Warrants exercisable as at June 30, 2021	–	—


		Weighted Average
		Exercise
	Number of	Price/Share
	warrants	(DKK)
Warrants granted as at December 31, 2019	1,932,156	1
Warrants granted	–	1
Warrants forfeited	(45,216)	1
Warrants cancelled	(22,032)	1
Warrants granted as at June 30, 2020	1,864,908	1
Warrants exercisable as at June 30, 2020	–	—

Employees will be entitled to receive a number of warrants based on the individual employee’s grade and performance for 2021. The warrants will be granted in December 2021 at the share price equal to the fair market value thereof on the date of grant and will vest monthly over 36 months beginning January 1, 2022.

For the three months ended June 30, 2021 and 2020, a service cost of $0.4 million and $0.5 million has been recognized in this period for warrants that were granted in previous periods and not fully vested as of the beginning of this period, and a proportion of the cost related to warrants expected to be granted in December 2021 and 2020, respectively.

For the six months ended June 30, 2021 and 2020, a service cost of $0.7 million and $1.2 million has been recognized in this period for warrants that were granted in previous periods and not fully vested as of the beginning of this period, and a proportion of the cost related to warrants expected to be granted in December 2021 and 2020, respectively.

Subsequent to the Company’s initial public offering completed in February 2021 ("IPO"), determining the initial fair value and subsequent accounting for equity awards require significant judgment regarding expected life and volatility of an equity award; however, as a public listed company there is objective evidence of the fair value of an ordinary share on the date an equity award is granted. Due to the fact that as of 2021, warrants will be granted at the share price on the date of grant, fair value comprises a time value which is significantly affected by the expected life and estimated volatility. The expected life of a warrant is based on the assumption that the holder will not exercise until after the equity award is fully vested. Actual exercise patterns may differ from the assumption used herein. The estimated volatility is based on peer group data and reflects the assumption that the historical volatility over a period similar to the life of the warrant is indicative of future trends, which may not necessarily be the actual outcome. The peer group consists of listed companies that management believes are similar to the Company in respect to industry and stage of development. Even with objective evidence of the fair value of an ordinary share, small changes in any other individual assumption or in combination with other assumptions could have resulted in significantly different valuations.

Capital Structure and Financial Matters

6 Months Ended

Jun. 30, 2021

Capital Structure and Financial Matters

Capital Structure and Financial Matters

Note 6. Capital Structure and Financial Matters

Share Capital – Ordinary Shares

The following are changes in the Company’s share capital for the period ended June 30, 2021:


	Number of	Share Capital
	Ordinary Shares	(DKK in thousands)
Share capital, December 31, 2020	16,198,668	16,198
Capital increase at February 9, 2021 for initial public offering	3,000,000	3,000
Share capital, June 30, 2021	19,198,668	19,198

Events After the Reporting Period

6 Months Ended

Jun. 30, 2021

Events After the Reporting Period

Events After the Reporting Period

Note 7. Events After the Reporting Period

Commencement of research laboratory facility

On October 23, 2020, we entered into a lease agreement for 518 square meters of laboratory space in Hørsholm, Denmark commencing on August 13, 2021 for a term of 10 years with a subsequent 12-month cancellation notice period.

The initial monthly payment for this laboratory space is expected to be between $16,000 and $18,000 and throughout the term, the lease is subject to annual increases ranging from two to four percent on the annualized lease payment amount.

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2021

Summary of Significant Accounting Policies

Basis of preparation

Right-of-use assets

Right-of-use assets

The Company’s right-of-use assets are presented within property and equipment.

Property and equipment

Property and equipment

Assets		Useful life
Properties		Shorter of lease term and useful life of the asset
Other equipment		3 – 6 years

Reclassifications of prior period presentation

Certain items in prior year condensed consolidated financial statements have been reclassified to conform to the current period’s presentation.

Standards issued but not yet effective

There were a number of standards and interpretations which were issued but were not yet effective at June 30, 2021 and have not been adopted for these financial statements, including:

●

Amendments to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or Non-current (January 1, 2023)

●

Amendment to IAS 37 Provisions, contingent liabilities and contingent assets, Onerous Contracts— Cost of Fulfilling a Contract (January 1, 2022)

●

Amendments to IAS 16 Property, Plant and Equipment, proceeds before intended use (January 1, 2022)

●

Annual Improvements 2018-2020 (January 1, 2022)

●

Amendment to IAS 1 Presentation of Financial Statements: Disclosure of Accounting Policies (January 1, 2023)

●

Amendment to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors: Definition of Accounting Estimates (January 1, 2023)

●

Amendments to IFRS 16 Leases: COVID-19-Related Rent Concessions beyond June 30, 2021 (April 1, 2021)

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2021

Summary of Significant Accounting Policies

Summary of estimated useful lives of assets

Assets		Useful life
Properties		Shorter of lease term and useful life of the asset
Other equipment		3 – 6 years

Share-Based Payments (Tables)

6 Months Ended

Jun. 30, 2021

Share-Based Payments

Schedule of granted warrants


		Weighted Average
		Exercise
	Number of	Price/Share
	warrants	(DKK)
Warrants granted as at December 31, 2020	2,228,076	1
Warrants granted	63,809	1
Warrants forfeited	(7,566)	1
Warrants cancelled	(10,404)	1
Warrants granted as at June 30, 2021	2,273,915	1
Warrants exercisable as at June 30, 2021	–	—


		Weighted Average
		Exercise
	Number of	Price/Share
	warrants	(DKK)
Warrants granted as at December 31, 2019	1,932,156	1
Warrants granted	–	1
Warrants forfeited	(45,216)	1
Warrants cancelled	(22,032)	1
Warrants granted as at June 30, 2020	1,864,908	1
Warrants exercisable as at June 30, 2020	–	—

Capital Structure and Financial Matters (Tables)

6 Months Ended

Jun. 30, 2021

Capital Structure and Financial Matters

Schedule of changes in the share capital


	Number of	Share Capital
	Ordinary Shares	(DKK in thousands)
Share capital, December 31, 2020	16,198,668	16,198
Capital increase at February 9, 2021 for initial public offering	3,000,000	3,000
Share capital, June 30, 2021	19,198,668	19,198

Summary of Significant Accounting Policies - Estimated useful lives of assets (Details) - Other equipment	6 Months Ended
	Jun. 30, 2021
Minimum
Disclosure of detailed information about property, plant and equipment [line items]
Useful lives	3 years
Maximum
Disclosure of detailed information about property, plant and equipment [line items]
Useful lives	6 years

Share-Based Payments - Warrants (Details) $ in Millions		3 Months Ended		6 Months Ended
Share-Based Payments - Warrants (Details) $ in Millions	Jan. 04, 2021 kr / shares	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2021 kr / shares	Jun. 30, 2020 USD ($)	Jun. 30, 2020 kr / shares
Share-Based Payments
Warrants as a percentage of outstanding shares				11.80%		12.30%
Warrants
Share-Based Payments
Vesting period				36 months
Warrants granted, price per share					kr 1		kr 1
Estimated fair value of warrants \| $		$ 0.4	$ 0.5	$ 0.7		$ 1.2
Ordinary shares \| Stock Split
Share-Based Payments
Nominal value per share prior to stock split	kr 2
Nominal value per share	kr 1
Ordinary shares \| Warrants \| Stock Split
Share-Based Payments
Increase in number of warrants, ratio	36
Warrants granted exercise price, prior to stock split	kr 2
Warrants granted, price per share	kr 1

Share-Based Payments - Schedule of Warrants (Details) - Warrants	6 Months Ended
	Jun. 30, 2021 kr / shares	Jun. 30, 2020 kr / shares
Number of warrants outstanding
Warrants granted at beginning of period	2,228,076	1,932,156
Warrants granted	63,809
Warrants forfeited	(7,566)	(45,216)
Warrants cancelled	(10,404)	(22,032)
Warrants granted at end of period	2,273,915	1,864,908
Weighted Average Exercise Price/Share (DKK)
Warrants granted at beginning of period, price per share	kr 1	kr 1
Warrants granted, price per share	1	1
Warrants forfeited, price per share	1	1
Warrants cancelled, price per share	1	1
Warrants granted at end of period, price per share	kr 1	kr 1

Capital Structure and Financial Matters - Changes in Share Capital (Details) kr in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2021 USD ($) shares	Jun. 30, 2021 DKK (kr) shares
Capital Structure and Financial Matters
Equity \| $	$ 7,038
Equity \| $	21,829
Share capital
Capital Structure and Financial Matters
Equity	2,648	kr 16,198
Equity	$ 3,132	19,198
Share capital \| Initial Public Offering
Capital Structure and Financial Matters
Capital increase at February 9, 2021 for initial public offering \| kr		kr 3,000
Ordinary shares
Capital Structure and Financial Matters
Share capital, shares, beginning of year	16,198,668	16,198,668
Share capital, shares, end of the period	19,198,668	19,198,668
Ordinary shares \| Initial Public Offering
Capital Structure and Financial Matters
Capital increase at February 9, 2021 for initial public offering, shares	3,000,000	3,000,000

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

Events After the Reporting Period (Details) - Commencement of research laboratory facility lease - Hrsholm, Denmark	Aug. 13, 2021 USD ($) m²
Disclosure of non-adjusting events after reporting period [line items]
Lease space \| m²	518
Lease term	10 years
Notice period for cancellation	12 months
Minimum
Disclosure of non-adjusting events after reporting period [line items]
Lease monthly payment	$ 16,000
Percentage of increase in annual lease payment	2.00%
Maximum
Disclosure of non-adjusting events after reporting period [line items]
Lease monthly payment	$ 18,000
Percentage of increase in annual lease payment	4.00%